Brokerages Set ICU Medical, Inc. (NASDAQ:ICUI) PT at $179.33

ICU Medical, Inc. (NASDAQ:ICUI) has earned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $179.3333.

Several research analysts have recently issued reports on the company. Piper Sandler increased their price target on ICU Medical from $172.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Sunday, February 15th. KeyCorp boosted their price target on shares of ICU Medical from $175.00 to $180.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd.

Hedge Funds Weigh In On ICU Medical

A number of hedge funds have recently modified their holdings of the stock. Maryland State Retirement & Pension System increased its stake in ICU Medical by 2.0% in the fourth quarter. Maryland State Retirement & Pension System now owns 3,619 shares of the medical instruments supplier’s stock valued at $516,000 after purchasing an additional 70 shares in the last quarter. Arizona State Retirement System boosted its stake in ICU Medical by 1.3% in the 3rd quarter. Arizona State Retirement System now owns 6,903 shares of the medical instruments supplier’s stock worth $828,000 after purchasing an additional 91 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in shares of ICU Medical by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock valued at $803,000 after purchasing an additional 100 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after buying an additional 101 shares during the period. Finally, Lido Advisors LLC grew its holdings in shares of ICU Medical by 4.5% during the fourth quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier’s stock worth $354,000 after buying an additional 106 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Trading Down 4.0%

ICU Medical stock opened at $136.74 on Tuesday. ICU Medical has a 52-week low of $107.00 and a 52-week high of $160.29. The company has a quick ratio of 1.15, a current ratio of 2.39 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $3.38 billion, a price-to-earnings ratio of 6,840.42, a PEG ratio of 2.06 and a beta of 0.79. The firm has a 50-day moving average price of $149.53 and a two-hundred day moving average price of $137.72.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.23. ICU Medical had a return on equity of 7.33% and a net margin of 0.03%.The business had revenue of $535.94 million during the quarter, compared to the consensus estimate of $541.20 million. During the same period in the previous year, the firm posted $2.11 earnings per share. The business’s revenue was down 14.1% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Sell-side analysts expect that ICU Medical will post 4.11 earnings per share for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.